Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. simecos

Simecos SIGNED

A New Adjuvant Nutraceutical from the North Atlantic Ocean for Breast, Lung and Pancreatic Cancer Patients

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 Simecos project word cloud

Explore the words cloud of the Simecos project. It provides you a very rough idea of what is the project "Simecos" about.

biological    prove    2020    shrimp    pay    82    diagnosed    2002    complementary    atlantic    give    trial    village    discovered    manufacturing    levels    supplements    life    fishery    fishing    anti    95    siglufj    clinically    chitooligosaccharides    effect    2    ph1    fatigue    nutraceutical    enzyme    started    thanks    cancer    return    feasibility    decrease    inhibition    optimise    hence    treatment    780    expansion    30    simecos    considering    solutions    confirmed    industry    clinical    trade    diseases    rdur    vitro    market    north    20    validate    2008    genis    worsen    therapeutic    respectively    forefront    extracted    biotechnology    pain    chitin    inflammation    effectiveness    iceland    business    molecules    purified    budget    profit    ouml    entail    rates    patients    breast    investment    exoskeleton    proven    survival    tumour    validated    chemotherapy    crisis    chos    compounds    adjuvant    2024    chitinase    18m    human    lung    vivo    quality    45m    ph2    opportunity    pancreatic    roi    health    9    inflammatory    ykl    marine   

Project "Simecos" data sheet

The following table provides information about the project.

Coordinator		 GENIS HF 

Organization address
address: ADALGOTU 34
city: SIGLUFJORDUR
postcode: 580
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Iceland [IS]
 Project website https://simecos.benecta.is
 Total cost 2˙180˙387 €
 EC max contribution 1˙526˙271 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-02-01   to  2020-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GENIS HF IS (SIGLUFJORDUR) coordinator 1˙526˙271.00

Map

 Project objective

Genis is based in Siglufjördur, a village in the North Iceland traditionally focused on the fishing industry. After the fishery crisis worsen in 2008, Siglufjördur started to pay attention to the marine biotechnology, with Genis at the forefront. Hence, since 2002, we develop health products based in T-ChOS™ (Therapeutic Chitooligosaccharides), which are compounds obtained from chitin extracted from the North Atlantic shrimp exoskeleton. T-ChOS™ show a strong anti-inflammatory effect based in a novel biological pathway discovered by Genis: Inhibition of the YKL-40 chitinase enzyme, whose levels are very high in several diseases as cancer. Our in vitro, in vivo and human studies prove that T-ChOS™ can decrease inflammation and enhance tumour response to chemotherapy. During the Ph1 project, we confirmed the feasibility of developing a nutraceutical based on T-ChOS™ to use as an adjuvant to chemotherapy in cancer patients. In this Ph2 project, we aim to optimise manufacturing, validate through a clinical trial and bring to market SIMECOS: A nutraceutical for cancer patients derived from chitin purified T-ChOS™ molecules. SIMECOS targets lung, breast and pancreatic cancer patients, with survival rates after 5-year of 20%, 82.2% and 5.2%, respectively. SIMECOS is expected to increase their quality of life, thanks to its proven effects to decrease pain and fatigue. The high trends (30%-95%) among cancer patients to use complementary supplements entail a great business opportunity for SIMECOS as in Europe, there are more than 780,000 patients per year diagnosed with breast, pancreatic and lung cancer looking for solutions to decrease chemotherapy side effects and improve the effectiveness of their treatment. Clinically validated SIMECOS will help these patients. We expect SIMECOS to reach the market in 2020. By 2024, after our European expansion, SIMECOS will give a profit of €10.45M and considering a Phase 2 budget of €2.18M, the return-on-investment (ROI) will be 9.9

 Deliverables

List of deliverables.
SIMECOS web page Websites, patent fillings, videos etc. 2020-03-19 15:44:56

Take a look to the deliverables list in detail:  detailed list of Simecos deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SIMECOS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SIMECOS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

RoboSynFarm (2019)

Robotic Synthesis Farm

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

Woodywood pickering (2019)

Bio-based (fully renewable) cost effective Polymer for new generation of ecological Coatings leveraging a disruptive innovation in the use of Pickering emulsion.

Read More